Differentiated thyroid carcinoma: An update

Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer. Particularly the incidence of small clinically indolent tumors has been increasing significantly during the last decades because of increased diagnostic scrutiny, while the DTC-related mortality remained unchanged. In light of the increased awareness of the significant risk of detecting clinically indolent tumors and the potential harm and burden associated with overly diagnosis and the treatment, the approach towards management of DTC recently underwent a critical appraisal. The focus lays on reducing the unnecessary burden for patients with very low risk DTC and the correct identification of those who require treatment that is more intensive and/or follow-up. Management of DTC in-cludes a range of different modalities, making multidisciplinary collaboration expedient. In this review, we elaborate on the recent developments in diagnosis, staging and management of DTC with specific focus on the more individualized risk assessment-based approach. (c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Automated summary

Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer, and the incidence of small clinically indolent tumors has been increasing. However, DTC-related mortality has remained unchanged. The management of DTC recently underwent a critical appraisal, focusing on reducing unnecessary burden for low-risk patients and identifying those who require more intensive treatment and follow-up. This review discusses recent developments in diagnosis, staging, and management of DTC, emphasizing an individualized risk assessment-based approach.